VCEL News and Press, Vericel Corporation From 12/28/23

2023-12-28 23:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-28 07:20:44 ET More on MediWound, Vericel, etc. MediWound Ltd. (MDWD) Q3 2023 Earnings Call Transcript Vericel Corporation (VCEL) Q3 2023 Earnings Call Transcript Vericel Corporation 2023 Q3 - Results - Earnings Call Presentation 3M to join MediWound ...

2023-11-17 18:40:33 ET Summary Delcath's Hepzato Kit is the only liver directed FDA approved treatment for mUM, a rare form of cancer. It will launch in the US in January. The treatment had a 36.3% objective response rate, outperforming the best available alternative treatment by ...

2023-11-15 11:15:00 ET Summary Equity markets declined in Q3 2023 as concerns over higher interest rates and a potential recession grew. Large-cap stocks outperformed small-cap stocks, largely due to the strong performance of mega-cap technology stocks. Conestoga's small-cap g...

2023-11-08 14:43:24 ET Vericel Corporation (VCEL) Q3 2023 Earnings Conference Call November 8 2023 8:30 AM ET Company Participants Eric Burns - Vice President, Finance and Investor Relations Nick Colangelo - President and Chief Executive Officer Joe Mara - Chief ...

2023-11-08 07:57:33 ET Vericel press release ( NASDAQ: VCEL ): Q3 GAAP EPS of -$0.08 beats by $0.04 . Revenue of $45.6M (+18.1% Y/Y) beats by $0.45M . MACI net revenue of $37.6 million, Epicel net revenue of $7.4 million and NexoBrid net revenue ...

Record Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year MACI Revenue Growth of 21% to $37.6 Million Full-Year 2023 Revenue Guidance Raised to $192.5-197.5 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 0...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Vericel Corporation (VCEL) is expected to report $-0.13 for Q3 2023

2023-11-07 12:03:23 ET More on Vericel Vericel: A Knee-Jerk 'Hold' Worth Its Salt Seeking Alpha’s Quant Rating on Vericel Historical earnings data for Vericel Financial information for Vericel For further details see: Vericel Q3 2023 Earnin...